GO
Loading...

Enter multiple symbols separated by commas

Celgene Corp

More

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Jobless claims lowest since 2000. April 30- U.S. stocks, led by the Nasdaq, sold off on Thursday as Apple shares declined, and tech and biotech quarterly results disappointed. The Nasdaq biotech index dropped 3.1 percent on Thursday, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue.

  • NEW YORK, April 30- Stock markets worldwide posted a second straight session of losses on Thursday after more weak earnings reports, with all three major U.S. indexes plunging more than 1 percent. Celgene led a fall in U.S. biotech stocks, while shares of Harman International Industries fell 7 percent after the maker of audio systems cut its 2015 profit forecast.

  • April 30- U.S. stocks sold off on Thursday, led by a drop in the Nasdaq, as Apple shares declined and results in tech and biotech names disappointed. The Nasdaq biotech index dropped 3.1 percent, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue. Apple was down 2.7 percent at $125.15 and was the biggest drag on the Dow, S&P 500...

  • And that kind of colored the statement more hawkish for the Fed, "said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama. The Nasdaq biotech index dropped 3.2 percent, led by a 3.9 percent fall in Celgene, which reported lower-than-expected quarterly revenue. The company limited the availability of the Apple Watch after a key...

  • *Apple and Celgene weigh on Nasdaq, S&P 500. April 30- Wall Street was lower in midday trading on Thursday as Apple weighed on major indexes and investors digested a mixed batch of economic data. Apple fell as much as 2.5 percent to $125.45 and was the biggest drag on the Dow, S&P 500 and the Nasdaq.

  • NEW YORK, April 30- Stock markets worldwide stumbled for a second straight day on Thursday after more weak earnings reports, while the dollar trimmed losses after hitting fresh nine-week lows. Weak quarterly earnings from Celgene led a fell in U.S. biotech shares, while shares of Harman International Industries fell over 7 percent after the maker of audio...

  • US STOCKS-Wall St opens lower as Apple, Celgene weigh Thursday, 30 Apr 2015 | 10:39 AM ET

    *Apple and Celgene weigh on Nasdaq, S&P 500. April 30- Wall Street opened lower on Thursday as Apple weighed on the major indexes and Celgene led a fall in biotech stocks, more than offsetting encouraging economic data. The company limited availability of the Apple Watch after a key component supplied by a Chinese company was found to be defective, according to the...

  • April 30- U.S. biotechnology company Celgene Corp posted a lower-than-expected quarterly revenue, hit by a stronger dollar, but said the dollar would not hurt full-year sales and profit more that it had already forecast. Celgene in late January had forecast 2015 adjusted profit of $4.60- $4.75 per share, on net product sales of $9.0- $9.5 billion, including a near...

  • April 30- Celgene Corp's quarterly profit more than doubled, driven by higher demand in the United States for its flagship multiple myeloma drug, Revlimid. The company's net profit rose to $718.9 million, or 86 cents per share, in the first quarter ended March 31, from $279.7 million, or 33 cents per share on a stock split-adjusted basis, a year earlier.

  • Market digs for next clue for data dependent Fed Thursday, 30 Apr 2015 | 6:03 AM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • What you need to know for Thursday trading Wednesday, 29 Apr 2015 | 5:33 PM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • Cramer: Wall Street insanity playing a cruel joke? Monday, 27 Apr 2015 | 6:16 PM ET
    Apple

    Jim Cramer ponders if Wall Street has completely lost its marbles, or if there could be bigger trends at work behind the scenes impacting investors.

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • LONDON, April 24- AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash. Chief Executive Pascal Soriot, however, said he had been looking for a partner in blood cancers since last year and by teaming up with U.S.-based Celgene, a...

  • AstraZeneca eyes new cancer deals after Nexium hit Friday, 24 Apr 2015 | 3:35 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca has sharpened its focus on cancer drugs as it looks beyond a hit to sales from the launch of cheap copies of its acid pill Nexium.

  • LONDON, April 24- AstraZeneca has sharpened its focus on cancer drugs with two new deals as it looks beyond a hit to sales and profits from the launch of cheap copies of its popular stomach acid pill Nexium in the vital U.S. market. AstraZeneca will get an upfront payment of $450 million from Celgene, while Innate will receive an initial $250 million from...